Screening for Barrett's esophagus (BE) with conventional esophagogastroduodenoscopy (C-EGD) is expensive. We assessed the performance of a clinic-based, single use transnasal capsule endoscope (EG Scan II) for the detection of BE, compared to C-EGD as the reference standard.
R ecent society guidelines have provided more support to screening individuals with multiple risk factors for Barrett's esophagus (BE) and esophageal adenocarcinoma, such as chronic reflux symptoms, central obesity, and a family history of esophageal adenocarcinoma or BE, 1, 2 although the number of risk factors that may trigger a decision to screen and, more importantly, the tools to screen remain unclear.
Although conventional esophagogastroduodenoscopy (C-EGD) remains the reference standard test to diagnose BE, it is not suitable for widespread screening because of direct and indirect costs associated with sedation, recovery, and monitoring. 3 The technical success rate of unsedated transnasal endoscopy (TNE) is comparable with C-EGD and the former was more preferred by patients. 4 However, the conventional TNE devices still require dedicated endoscopy suites with specialized equipment and decontamination facilities, hence, they have limited potential for widespread use in population screening. 5 Recent reports have demonstrated the acceptability, safety, and accuracy of modified endoscopic transnasal techniques (EndoSheath) 6, 7 in screening for BE. The EndoSheath transnasal esophagoscope is portable and uses a disposable sheath with a biopsy channel that covers the endoscope to reduce the risk of cross contamination, but it still requires cleaning of the scope with alcohol wipe and an enzymatic detergent after every use.
The EG Scan II (second generation) transnasal video esophagoscope (Intromedic Ltd, Seoul, South Korea) incorporates a disposable probe that omits the need for reprocessing. Moreover, it is highly compact and portable, and therefore can be used in the clinic or any other setting with rapid turnaround of patients. The aim of the current study was to assess the technical feasibility, quality, safety, acceptability, and accuracy of clinicbased TNE using the EG Scan compared with C-EGD as the reference standard.
Materials and Methods

Study Design and Settings
This was a prospective diagnostic cohort study performed in 3 tertiary referral centers, 2 in the United Kingdom (Nottingham and Cambridge University Hospitals) and 1 in the United States (Mayo Clinic, Rochester, MN). All procedures were performed between July 2012 and October 2015 and all participants provided written informed consent. The trial received approval from the East Midlands research ethics committee (United Kingdom) and from the Mayo Clinic Institutional Review Boards. It was prospectively registered (ISRCTN registry identifier: 70595405; ClinicalTrials.gov identifier: NCT02066233). The research was conducted and reported according to the Standards for the Reporting of Diagnostic Accuracy Studies statement. 8 All authors had access to the study data and reviewed and approved the final manuscript.
Participants
Consecutive adult patients referred for clinical C-EGD with and without histologically confirmed BE of any length were invited to participate. BE patients were undergoing clinically indicated endoscopy for surveillance or therapy of BE-related neoplasia. Patients without known BE were undergoing endoscopy for other clinical indications, which included dyspepsia, heartburn, dysphagia, and nausea/vomiting. Exclusion criteria were recurrent epistaxis (more than once a week), complete nasal obstruction, diseases of the nasal cavity, and anticoagulant use. All eligible patients were identified from the endoscopy referral database and approached by the study coordinators either via a letter or telephone call to inform them of study details. Subjects were asked to express their interest in taking part or not either at the time of the telephone call or by returning a prepaid self-addressed reply envelope to the study coordinators.
Interventions
All patients underwent TNE first using the EG Scan (index test) followed by C-EGD (reference standard) on the same day by 2 different operators who were blinded to the findings of each other. TNE procedures were performed by certified endoscopists (S.S.S. in Nottingham; M.D.P. in Cambridge; P.G.I. and M.H. at Mayo Clinic) who had limited prior experience in using the EG Scan device (performed 1-3 procedures in the past), but had performed more than 1000 C-EGD procedures. P.G.I also had experience in performing TNE (n ¼ 200).
At both procedures, a note was made of any suspected BE and the segment length was defined using the Prague criteria. 9 Demographic and procedure data were collected and patients were asked to fill in validated questionnaires within 14 days after the procedures.
The EG Scan II system
The second-generation EG Scan system (Figure 1 ) components are described in Supplementary Table 1 .
What You Need to Know
Background Screening for Barrett's esophagus (BE) with conventional esophagogastroduodenoscopy (C-EGD) is not cost effective Unsedated transnasal endoscopy (TNE) is safe, accurate and acceptable alternative to C-EGD. Existing TNE devices have limited applicability for widespread use in the community setting due to limited portability and the need for decontamination.
Findings
Clinic-based TNE using the EG Scan device was safe, feasible, and acceptable. A higher proportion of patients preferred the EG Scan over C-EGD regardless of the use of sedation for the latter. The EG Scan was accurate for the detection of BE of any length with superior accuracy for long-segment compared with short-segment BE.
Implications for patient care
This device could potentially serve as a tool for screening populations at risk for BE. Future studies should evaluate the utility of this technique in the intended screening population. In particular, important aspects, such as participation rates, operator training, and yield of screening, need to be explored.
Endoscopy Procedures
The EG Scan procedure was performed in an outpatient clinic room with the patient sitting in a chair next to the physician's desk. Before commencing the procedure, participants were given a 100-mL liquid oral drink, which is a mixture of water, orange cordial flavoring, a mucolytic (10 mL of 200 mg/mL N-acetylcysteine), and an antifoaming agent (1 mL of simethicone 40 mg/mL) to improve visualization of the mucosa (UK centers only). A topical aerosol spray (lidocaine hydrochloride 5% and phenylephrine hydrochloride 0.5%) was applied to the patient's nares (3-4 sprays) 3-5 minutes before the procedure. The probe was introduced into the right or left nares and advanced into the proximal esophagus under direct vision. The operator inspected the esophagus and the gastroesophageal junction (indicated by the top of the proximal gastric folds) both in forward and retroflexion views. Following the procedure, the probe was disconnected from the hand-held controller and discarded. The system was dismantled and stored in the accompanying suitcase ( Figure 1A ).
The C-EGD procedures were performed in the endoscopy suite using a 9.8-mm diameter high-definition endoscope (GIF-260H, Olympus Keymed, Essex, UK; or GIF-H180, Olympus America, Center Valley, PA). Patients in the UK centers were offered either a topical anesthetic spray (applied to the posterior pharynx, 5-10 sprays, lidocaine 10 mg/dose, xylocaine, AstraZeneca, Luton, UK) or conscious sedation (intravenous midazolam with or without pethidine or fentanyl) for their C-EGD procedures, whereas all the US participants received conscious sedation.
Patient Questionnaires
All post-procedure questionnaires were administered by the study coordinators and completed by patients with the endoscopists blinded. Patients' tolerability was measured using a validated 10-point visual analogue scale (VAS). 10 Patients were asked to describe their overall experience of both procedures by placing a cross on a line from 0 (worst ever experience) to 10 (best ever experience). Patients were asked which procedure they would prefer to have in the future if clinically indicated (EG Scan, C-EGD, or either). 27 Copyright John Wiley and Sons).
Tolerability and preference questionnaires were completed using prepaid self-addressed return envelopes at least 24 hours after procedures to allow for the complete resolution of sedation effects. We also measured the degree of gagging, choking, discomfort, and nasal pain immediately after EG Scan using the same scale where 0 is none and 10 is severe.
Patients were also asked to complete a validated short form Spielberger State Trait Anxiety Inventory questionnaire 11 at baseline and after both EG Scan and C-EGD procedures. Spielberger State Trait Anxiety Inventory scores were calculated as per the developers' guidelines, with clinically significant anxiety considered to be a score of !40.
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Outcome Measures
Study outcome measures included the technical feasibility and quality of the endoscopic examinations measured as: (1) rate of successful intubation (the ability to traverse the upper esophageal sphincter and visualize the esophageal mucosa); (2) rate of complete visualization of the tubular esophagus, squamocolumnar junction, and gastroesophageal junction; and (3) duration of EG Scan examination (time from intubation to extubation). Safety of procedures was measured as the rate of serious adverse events or need for hospitalization assessed immediately and within 14 days (telephone call from the study coordinator) after procedures. Patients' acceptability of both procedures was measured using validated questionnaires as detailed previously.
The accuracy of EG Scan (index test) in detecting: (1) any length BE, (2) long-segment BE (LSBE) defined as circumferential (C) or maximal (M) length !3 cm by Prague criteria, 9 and (3) short-segment BE (SSBE) defined as C or M <3 cm using C-EGD as the reference standard was measured.
Statistical Analysis
Data on the diagnostic accuracy and acceptability of this novel screening tool compared with C-EGD were not available to reliably inform sample size calculations. We assessed a group of 200 patients with the aim to include approximately 50% with known BE (prevalence). Based on clinical experience, we expected the EG Scan sensitivity to be 0.85-0.90. In this scenario, a sample size of 141-200 patients gives a margin of error of AE 0.07, which is clinically meaningful to evaluate this device as a diagnostic test for BE. 12 We used paired Student t test (normally distributed differences) and Wilcoxon signed rank test (nonnormally distributed differences) to compare measurements of continuous variables. The chi-square or Fisher exact tests were used to compare categorical variables. Statistical computations were performed using Stata version 12.0 software (Stata Corporation, College Station, TX).
Results
Baseline Characteristics
Two hundred patients were enrolled (Nottingham, n ¼ 50; Cambridge, n ¼ 50; Mayo Clinic, n ¼ 100). The mean (AE standard deviation) age was 58 years (AE 14) and BE prevalence was 53%. The median (interquartile range [IQR]) length of BE was C0 (IQR, 0-2) and M2 (IQR, 1-4). Baseline characteristics of all participants are outlined in Table 1 .
Technical Feasibility, Quality, and Safety A total of 178 out of 200 patients (89%) completed both procedures and are included in the analysis. Twenty-two patients (11%) failed EG Scan because of the inability to intubate the nasopharynx. Those were equally split between the UK (n ¼ 11; 5.5%) and the US (n ¼ 11; 5.5%) centers (Figure 2 ). The rate of complete visualization was similar between the 2 techniques ( Table 2 ). The mean duration of the EG Scan examination was 4.0 (AE 4.0) minutes. A total of 120 out of 178 (67%) C-EGD procedures were performed under sedation. Of those, 110 received intravenous midazolam (median dose, 5 mg; IQR, 3-6) with or without intravenous pethidine (n ¼ 35; median dose, 50 mg; IQR, 0-62.5) or intravenous fentanyl (n ¼ 70; median dose, 100 mg; IQR, 75-100). Ten patients received propofol sedation.
There were five cases of nonserious adverse events, which included: (1) probe technical failure (n ¼ 2) toward the end of procedures where the up/down lever at the handle failed to achieve tip deflection and the procedure was terminated; (2) 2 patients (1.1%) experienced vasovagal symptoms after abdominal distention secondary to air insufflation during the procedure, and this self-terminated after a short period of observation; and (3) 1 patient (0.55%) developed self-limiting epistaxis. All those 5 patients were included in the analysis. No serious adverse events occurred.
Acceptability
The overall tolerability (VAS scores) was better with EG Scan compared with C-EGD (Table 2) . When stratified by sedation and center location, the VAS scores were comparable between the EG scan and C-EGD in the subgroup of patients that either received sedation or where from the US center. There was a significant reduction in the mean (AE standard error of the mean) anxiety scores post EG Scan (30.5 AE 0.8; P ¼ .0003) and post C-EGD (28.7 AE 0.9; P < .0001) compared with baseline (33.4 AE 0.8).
Accuracy
A total of 94 out of the 178 patients (53%) had BE (n ¼ 40 LSBE; n ¼ 54 SSBE). Data on accuracy are shown in Table 3 . The EG Scan missed 9 cases of BE, 2 of those were LSBE (Figure 2 ). In both of those, the squamocolumnar junction was poorly visualized with white light imaging on C-EGD and had to be confirmed with narrow band imaging. Example findings of EG Scan are shown in Figure 3 .
Discussion
Principal Findings
Results from this multicenter study evaluating the clinical feasibility of using the EG Scan device as a clinic-based screening test for BE demonstrate that the procedure is safe, well tolerated, and accurate, when compared with C-EGD. Significantly more patients preferred the EG Scan over C-EGD independent of sedation use for the latter. The difference in technical success rate for EG Scan compared with C-EGD in this study was -11% (89% vs 100%, respectively). This is larger than expected compared with values reported in the literature. 4 All operators had a comparably limited experience of using the EG Scan at baseline; therefore, a learning curve that may impact on the technical and diagnostic performance of this technique might be present. We have previously demonstrated that studies using TNE <5.9 mm insertion diameter reported significantly higher success rates compared with those using !5.9 mm. 4 The insertion diameter of the EG Scan was 6.1 mm, which is relatively large compared with other modern TNE devices. 5 A third-generation EG Scan prototype with a smaller insertion diameter of 5.0 mm has been developed. This may allow for further improvements in device performance compared with the current prototype.
Results on accuracy of EG Scan for the detection of BE in this study were comparable with those reported for other conventional TNE devices (nonportable and nondisposable). 13, 14 Shariff et al 13 reported a sensitivity and specificity of 0.98 and 0.99, respectively, for TNE using a FUJINON endoscope (EG530N, FUJIFILM Europe GmbH, Düsseldorf, Germany) with a 5.9-mm insertion diameter. However, they only included patients with a minimum circumferential length BE of 2 cm and all procedures were performed in a dedicated endoscopy suite. Our data suggest that undertaking TNE in a clinic room using a significantly more compact device (EG Scan) can still achieve high sensitivity in this subgroup of patients with longer segment BE.
One limitation of the EG Scan compared with other TNE devices and C-EGD is the lack of a working channel, hence it is not possible to obtain biopsy samples from endoscopically suspected areas of BE. Nevertheless, it must be emphasized that we evaluated this device as a potential tool for future use in a 2-step BE screening program in the primary care setting. If such a program is implemented using this technology, then the issue of biopsy acquisition becomes less critical, because all cases with suspected BE will require a clinical C-EGD for surveillance biopsies and risk stratification as per current practice. The cost of the EG Scan probe compared with other tools needs to be considered; however, this can vary significantly depending on supply and demand. Moreover, there are several other important issues to consider when comparing the EG Scan with other screening tools, such as turnover time, screening uptake, NOTE. Data presented as number (%), mean AE standard deviation, or median (interquartile range). C-EGD, conventional esophagogastroduodenoscopy; VAS, visual analogue scale.
a Calculated for patients who were successfully intubated and underwent both procedures (n ¼ 178). Visualization was incomplete in 3 patients (EG Scan) because of secretions and 1 patient (C-EGD) because of intolerance with constant gagging despite sedation. b A total of 168/178 returned the tolerability (VAS) and preference questionnaires. c All patients in this subgroup received sedation for C-EGD. d A total of 119/168 expressed preference for either EG Scan or C-EGD, whereas the remaining 49/168 had no preference (either). accuracy, acceptability, yield for other pathologies, and impact on quality of life. These factors must be incorporated into a cost-effectiveness modelling study to evaluate different screening approaches. A capsule sponge (Cytosponge) coupled with a biomarker (TFF3) has been evaluated in a case-control and in a primary care setting. In the case-control study (1110 patients, 647 cases and 463 control subjects), 15 the success rate of the capsule sponge was 94% and the overall sensitivity and specificity for BE !C1 or !M3 were 0.80 (95% confidence interval, 0.76-0.83) and 0.92 (95% confidence interval, 0.90-0.95), respectively. In the primary care setting with a prevalence of 3%, the sensitivity and specificity of the test for the detection of BE !C1 were 0.73 and 0.94, respectively. 16 Screening using a nonendoscopic device was also found to be costeffective in a separate economic modelling study. 17 The procedure can be performed by less skilled operators with potential for widespread applicability. The sampling has advantages for the evaluation of cellular and molecular features suggestive of inflammation, infection, intestinal metaplasia, and dysplasia 18, 19 ; however, it will not provide real-time visualization of the BE segment and other high-risk features associated with it, such as erosive esophagitis, ulcers, strictures, and polypoid lesions ( Figure 3 ). All these trade-offs need to be carefully weighed when comparing different screening technologies.
Screening tests should be acceptable to patients with minimal psychological impact to improve the uptake and cost-effectiveness of the screening program. 20 Data from this study demonstrate a positive impact of EG Scan on patients' satisfaction with a significant reduction in anxiety scores after procedures. TNE screening for BE can be performed successfully by physician extenders after a short training program. 21 This may reduce operator costs and increase access to future screening programs. TNE screening was also found to be more cost-effective than C-EGD screening with lower direct and indirect costs.
3,22
Study Strengths and Limitations
This multicenter study had several strengths and limitations. The trial conduct and reporting conforms to current guidelines for undertaking diagnostic accuracy studies, which is an important strength. 8, 23 We used validated VAS 10 and 3-item (EG Scan or C-EGD or either) questionnaires to measure tolerability and preference, respectively. Those were self-administered at home with the endoscopist blinded to eliminate interviewer bias. 24 The response rate was 94% (168 out of 178) for both VAS and preference questionnaires (Table 2) , hence response bias remains unlikely. Moreover, patients were offered the choice of "either" for their procedure preference to minimize forced choice bias, where respondents who have no preference are forced to select an answer (EG Scan or C-EGD) that may or may not reflect their true feelings. 24 We cannot rule out social desirability or obsequiousness bias where respondents may alter their questionnaire responses in the direction they perceive to be desired by the investigator 24 ; however, this limitation pertains to most questionnaire study designs. Patients were not offered monetary compensation or any other incentive (eg, an earlier appointment) to participate in the study.
This was a nonrandomized cohort study and no pilot data were available to adequately inform sample size calculations. The order of procedures and operators should be randomized in future trials to eliminate bias in preference estimates toward 1 procedure or the other. Because of the performance of this study in tertiary centers using a case-control design, the prevalence of BE in this study was high compared with the general population. 6, 16 The diagnostic accuracy can be overestimated if the test is evaluated in patients already known to have the disease, rather than in a relevant screening population. 25 The proportion of false-positive diagnoses is higher and false-negative ones lower when the current sensitivity and specificity is applied to lower prevalence populations (Supplementary Box 1) . However, for this initial study because the prevalence of BE is low, 26 we opted to enrich the study population with patients known to have BE to obtain estimates of sensitivity and specificity.
We did not evaluate interobserver agreement. The EG Scan was less sensitive in detecting SSBE compared with LSBE. This could be caused by a limitation of the EG Scan imaging quality or could equally be a result of poor agreement between the EG Scan and C-EGD operators on the presence or absence of SSBE. Seven out of the 9 cases missed by the EG Scan had a circumferential length of 0 cm and maximal length of 1-2 cm (Figure 2 ). The interobserver agreement on presence of circumferential BE <1 cm is known to be poor (0.22) compared with BE !1 cm (0.72). 9 
Conclusions
Clinic-based TNE using the EG Scan was feasible, safe, and highly acceptable by patients compared with C-EGD. The overall technical success rate of EG Scan was lower than expected compared with literature estimates for the TNE technique. This could be caused by such factors as operator expertise and the insertion diameter of the EG Scan probe. EG Scan accuracy for the detection of BE was high. Future studies should evaluate the utility of this technique in the intended screening population. In particular, important outcomes, such as participation rates, learning curve, yield of screening, and costeffectiveness, need to be assessed.
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